Touchstone Innovations

Touchstone Innovations, the firm historically known as Imperial Innovations, is a London-based venture investor with a long track record commercializing hard technology emerging from leading UK universities. The platform was central to building the UK’s university-spinout ecosystem and has consistently backed biotech and medical device companies grounded in deep scientific IP. Although organizational structure has shifted across owners and successor entities over time, the underlying focus on translating academic research into venture-backable companies remains. The firm is not positioned as an AI-specific investor, and limited public information is available about current named investment partners under the Touchstone banner.

Touchstone invests across Seed, Series A, and Series B stages, with checks in the $1M to $5M range that allow it to support spinouts from formation through their first institutional growth rounds. Geographic focus is the United Kingdom, with particular concentration on companies emerging from London-area academic research institutions. The firm frequently syndicates with other UK life sciences specialists and Innovate UK-backed co-investors, providing follow-on capital across multiple rounds.

For academic and research-led founders, Touchstone offers a partner with deep familiarity with the realities of spinout creation, IP negotiation, and the particular cadence of clinical and regulatory milestones. Founders should expect technical diligence to dominate early conversations and equity negotiations to reflect the firm’s long history with university-linked structures. Pure software or commercial-stage founders without a deep science core will find better fits elsewhere. For UK-based scientific founders building biotech or medical device companies on substantive IP, Touchstone remains a relevant institutional partner.